Skip to Content

European Committee OKs Novartis Drug Rasilamlo

From Associated Press (February 18, 2011)

Swiss drug maker Novartis said Friday a European advisory committee gave a positive recommendation for its blood pressure treatment Rasilamlo.

The pill aims to treat high blood pressure that is not adequately controlled by either aliskiren or amlodipine alone. It combines the high blood pressure treatment Rasilez with the calcium channel blocker amlodipine.

The Committee for Medicinal Products for Human Use of the European Medicines Agency gave a positive opinion on the drug. A European Commission licensing decision is expected in about three months.

Novartis said about one billion people globally have high blood pressure, and it can damage vital organs like the heart, brain and kidneys.

The drug has been approved by the U.S. Food and Drug Administration under the brand name Tekamlo.

Posted: February 2011